These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19555375)

  • 21. Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shin HJ; Chung JS; Cho GJ
    Bone Marrow Transplant; 2005 Nov; 36(10):917-8. PubMed ID: 16113662
    [No Abstract]   [Full Text] [Related]  

  • 22. Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Matsue K; Aoki T; Odawara J; Kimura S; Yamakura M; Takeuchi M
    Leuk Res; 2009 Jun; 33(6):867-9. PubMed ID: 18951628
    [No Abstract]   [Full Text] [Related]  

  • 23. Hemopoietic stem cell transplantation from a donor with indeterminate HTLV-1 status.
    Au WY; Chan E; Lie AK
    Am J Hematol; 2007 Jun; 82(6):495. PubMed ID: 16929539
    [No Abstract]   [Full Text] [Related]  

  • 24. Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yamada K; Yasui M; Kondo O; Sato M; Sawada A; Kawa K; Inoue M
    Pediatr Blood Cancer; 2013 Aug; 60(8):E60-2. PubMed ID: 23468187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acute lymphoblastic leukemia in elderly: prognosis and treatment].
    Thomas X; Tavernier E; Le QH
    Bull Cancer; 2004 Sep; 91(9):713-20. PubMed ID: 15544997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The first case of acute lymphoblastic leukemia with the e19a2 BCR-ABL1 transcript: imatinib therapy followed by unrelated donor transplantation induces a durable molecular response.
    Jeon EK; Lim J; Kim M; Yahng SA; Lee SE; Cho BS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lee S
    Leukemia; 2011 Feb; 25(2):366-7. PubMed ID: 21072049
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Yanada M
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():479-82. PubMed ID: 17474451
    [No Abstract]   [Full Text] [Related]  

  • 28. [Management of acute lymphoblastic leukemia].
    Usui N
    Rinsho Ketsueki; 2008 Oct; 49(10):1374-85. PubMed ID: 18833922
    [No Abstract]   [Full Text] [Related]  

  • 29. Linking the hematopoietic microenvironment to imatinib-resistant Ph+ B-ALL.
    Dorshkind K; Witte ON
    Genes Dev; 2007 Sep; 21(18):2249-52. PubMed ID: 17875661
    [No Abstract]   [Full Text] [Related]  

  • 30. Adult ALL: where are we and where are we going?
    Larson RA
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):342-4. PubMed ID: 16163203
    [No Abstract]   [Full Text] [Related]  

  • 31. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.
    Fava C; Rege-Cambrin G; Busca A; Gottardi E; Daraio F; Saglio G
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S272-5. PubMed ID: 24290212
    [No Abstract]   [Full Text] [Related]  

  • 32. Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
    Gutiérrez-Aguirre H; García-Rodríguez F; Cantú-Rodríguez O; González-Llano O; Jaime-Pérez J; Gómez-Almaguer D
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):875-8. PubMed ID: 22252621
    [No Abstract]   [Full Text] [Related]  

  • 33. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A report of three patients treated with immunocell therapy with imatinib mesylate.
    Kaneko T; Goto S; Kushima Y; Miyamoto Y; Eriguchi M; Nieda M; Egawa K
    Anticancer Res; 2004; 24(5C):3303-9. PubMed ID: 15515425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia].
    Fløisand Y; Brinch L; Dybedal I; Gedde-Dahl T; Heldal D; Holme PA; Egeland T; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2563-6. PubMed ID: 19023351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperative Study SHOP/ALL-2005.
    Rives S; Camós M; Estella J; Gómez P; Moreno MJ; Vivanco JL; Melo M; Fernández-Delgado R; Verdeguer A; Fernández-Teijeiro A; Lendínez F; López-Almaraz R; Uriz JJ; Badell I;
    Br J Haematol; 2013 Aug; 162(3):419-21. PubMed ID: 23668628
    [No Abstract]   [Full Text] [Related]  

  • 37. Philadelphia positive acute lymphoblastic leukaemia of childhood.
    Jones LK; Saha V
    Br J Haematol; 2005 Aug; 130(4):489-500. PubMed ID: 16098062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
    Chaidos A; Kanfer E; Apperley JF
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):125-54. PubMed ID: 17448953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
    Swords R
    Drugs; 2007; 67(17):2655-6. PubMed ID: 18034599
    [No Abstract]   [Full Text] [Related]  

  • 40. [Current chemotherapy of adult acute lymphoblastic leukemia].
    Usui N
    Rinsho Ketsueki; 2010 Oct; 51(10):1549-57. PubMed ID: 20962489
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.